Sutro Biopharma (STRO)
Develops site-specific and dual-payload antibody-drug conjugates for oncology using cell-free protein synthesis.
Something off on this page? Send us feedback.
Develops clinical-stage oncology ADCs, including site-specific and dual-payload formats. Its XpressCF and XpressCF+ platforms combine cell-free protein synthesis with site-specific conjugation.
Develops clinical-stage oncology antibody-drug conjugates, or ADCs, designed around site-specific and novel formats. XpressCF is its integrated cell-free protein-synthesis platform, while XpressCF+ adds the site-specific conjugation platform used to design those formats, including dual-payload ADCs.
The post-review portfolio centers on wholly owned next-generation exatecan and dual-payload ADC programs, beginning with STRO-004. Research-and-development collaborations are also part of the operating model, while the company sought a partner for its deprioritized late-stage program.
Based in South San Francisco, the company reduced its internal operating footprint through 2025 restructuring. It exited its internal GMP manufacturing facility at year-end and externalized cell-free manufacturing to partners.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 6, 2026 | Stifel Nicolaus | Target | Target: — | Target: $48 |
| Jun 11, 2026 | Truist Financial | Target | Target: $15 | Target: $50 |
| May 28, 2026 | Barclays | Target | Target: — | Target: $56 |
| May 15, 2026 | Wedbush | Upgrade | Target: $8 | Target: $60 |
| May 15, 2026 | H.C. Wainwright | Target | Target: $12 | Target: $50 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $164.3M · Total debt $10.8M · Total assets $194.5M · Shareholders' equity −$103.3M
- Revenue
- $9.8M
- Operating income
- −$29.9M
- Net income
- −$38.5M
No dividends on record.
| Institutions | ≈ 99.69% | 16.53M shares | |
|---|---|---|---|
| 101 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 0.77% | 127.2K shares | |
| 11 holders · as of Sep 22, 2026 | |||
| Adds to | 100.46% | ||
16.58M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (16.58M in the company's Sep 23, 2026 report, 9.68M elsewhere); stakes use the report.
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 100.46%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Perceptive Advisors LLCInstitution | 7.87% | 1.30M | as of Jun 30, 2026 |
BVF Inc/ILInstitution | 7.55% | 1.25M | as of Jun 30, 2026 |
Affinity Asset Advisors, LLCInstitution | 7.07% | 1.17M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 6.77% | 1.12M | as of Jun 30, 2026 |
Samsara Biocapital, LLCInstitution | 6.41% | 1.06M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Oct 15, 2025 | David Pauling | officer: Chief Admin. Ofcr. & GC | +12,504 | $0.7992 |
| Oct 15, 2025 | Connie Matsui | director | +50,000 | $0.7990 |
| Oct 15, 2025 | Jane Chung | director, officer: Chief Executive Officer | +12,500 | $0.8009 |
| Oct 15, 2025 | Gregory K. Chow | officer: CFO | +19,750 | $0.8100 |
| Oct 15, 2025 | Hans-Peter Gerber | officer: CHIEF SCIENTIFIC OFFICER | +17,000 | $0.8004 |
- Pfizer
TIVDAK and integrin beta-6 ADCs overlap in solid tumors
- Whitehawk Therapeutics
PTK7 ADC in a recruiting Phase 1 solid-tumor trial
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Sutro Biopharma | $15.79 | −2.09% | $156.1M | — | — | 3.4 | −84.6% |
| Pfizer | $27.92 | −0.04% | $159.19B | 36.9 | 10.0 | 2.5 | +2.6% |
| Whitehawk Therapeutics | $3.85 | −4.83% | $230.3M | — | — | — | — |
| Median | 36.9 | 10.0 | 2.5 | +2.6% |